KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash & Equivalents: 2010-2024

Historic Cash & Equivalents for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $99.5 million.

  • Emergent BioSolutions' Cash & Equivalents rose 63.78% to $245.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.5 million, marking a year-over-year increase of 63.78%. This contributed to the annual value of $99.5 million for FY2024, which is 10.92% down from last year.
  • Emergent BioSolutions' Cash & Equivalents amounted to $99.5 million in FY2024, which was down 10.92% from $111.7 million recorded in FY2023.
  • Emergent BioSolutions' Cash & Equivalents' 5-year high stood at $642.6 million during FY2022, with a 5-year trough of $99.5 million in FY2024.
  • Its 3-year average for Cash & Equivalents is $284.6 million, with a median of $111.7 million in 2023.
  • As far as peak fluctuations go, Emergent BioSolutions' Cash & Equivalents skyrocketed by 270.26% in 2020, and later tumbled by 82.62% in 2023.
  • Emergent BioSolutions' Cash & Equivalents (MRY) stood at $621.3 million in 2020, then dropped by 7.28% to $576.1 million in 2021, then rose by 11.54% to $642.6 million in 2022, then crashed by 82.62% to $111.7 million in 2023, then fell by 10.92% to $99.5 million in 2024.
  • Its Cash & Equivalents stands at $99.5 million for FY2024, versus $111.7 million for FY2023 and $642.6 million for FY2022.